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Aims Hawthorn’s efficacy when added to contemporary evidence-based heart failure therapy is unknown. We aimed to
determine whether hawthorn increases submaximal exercise capacity when added to standard medical therapy.
Methods
and results
We performed a randomized, double-blind, placebo-controlled trial in 120 ambulatory patients aged 18 years with
New York Heart Association (NYHA) class II-III chronic heart failure. All patients received conventional medical
therapy, as tolerated, and were randomized to either hawthorn 450 mg twice daily or placebo for 6 months. The
primary outcome was change in 6 min walk distance at 6 months. Secondary outcomes included quality of life
(QOL) measures, peak oxygen consumption, and anaerobic threshold during maximal treadmill exercise testing,
NYHA classification, left ventricular ejection fraction (LVEF), neurohormones, and measures of oxidative stress
and inflammation. There were no significant differences between groups in the change in 6 min walk distance
(P ¼ 0.61), or on measures of QOL, functional capacity, neurohormones, oxidative stress, or inflammation.
A modest difference in LVEF favoured hawthorn (P ¼ 0.04). There were significantly more adverse events reported
in the hawthorn group (P ¼ 0.02), although most were non-cardiac.
Conclusion Hawthorn provides no symptomatic or functional benefit when given with standard medical therapy to patients with
heart failure.
This trial is registered in ClinicalTrials.gov ID: NCT00343902.
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Introduction
Contemporary therapies [i.e. angiotensin-converting enzyme-
(ACE) inhibitors, beta-blockers, spironolactone, implantable cardi-
overter–defibrillators, and biventricular pacemakers] have pro-
duced remarkable reductions in heart failure-related morbidity
and mortality. Despite these advances, both the length and
quality of life (QOL) for those with heart failure remain impaired
and improved treatment regimens are still needed.
Crataegus monogyna or hawthorn has been used for cardiac and
circulatory disorders since the first century AD.1 Hawthorn
demonstrates numerous properties that may be beneficial in
heart failure including anti-arrhythmic activities,2,3 and the ability
to increase coronary blood flow,4,5 and cardiac output.6 These
effects may be mediated by inhibition of phosphodiesterase types
III and IV,7,8 antioxidant activities9,10 and anti-inflammatory
effects.3,11 A meta-analyses of clinical trials concluded that haw-
thorn may be a safe and effective treatment for chronic heart
failure.12
Although most previous trials of hawthorn have reported
modest improvements in exercise capacity, QOL, and heart
failure-related symptoms,12 these studies are limited by their
short duration, lack of meaningful clinical outcomes for CHF,
unclear severity of study patients, and frequent absence of
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conventional, evidence-based, concomitant medical therapy. Using
a well-defined patient sample, meaningful standardized clinical out-
comes, longer study duration, and contemporary evidence-based
medical therapy, we conducted a randomized, placebo controlled,
double-blind clinical trial to determine the efficacy of a hawthorn
extract for the treatment of ambulatory patients with New York
Heart Association (NYHA) class II to III chronic heart failure.
Methods
The study protocol and all procedures were approved by the Univer-
sity of Michigan Medical School Institutional Review Board and were
overseen by an independent Data Safety Monitoring Board. All partici-
pants provided written informed consent. Ambulatory patients aged
18 years of age and older with a 3 months history of HF (NYHA
classes II-III) and a left ventricular ejection fraction (LVEF) 40% (by
radionuclide or contrast ventriculography or by echocardiography),
as assessed during usual clinical care within the 12 months prior to ran-
domization, were eligible for enrolment. Patients had to be receiving
standard medical therapy (in the absence of a contraindication or intol-
erance), defined as an angiotensin converting enzyme inhibitor or
angiotensin receptor antagonist, a beta-blocker and a diuretic. Poten-
tial subjects had to walk between 150 and 450 m during two 6 min
walk tests, conducted 2 weeks apart (screening and baseline visits,
respectively), to be deemed eligible for the study. Eligible subjects
were randomly assigned to receive either C. oxycantha extract, Cratae-
gus Special Extract WS 1442 (Crategutt forte, Willmar Schwabe Phar-
maceuticals, Karlsruhe, Germany), 450 mg orally twice daily, or a
matching placebo. Patients were seen at the study clinic 3 months
and 6 months after the baseline visit. A detailed description of the
study inclusion and exclusion criteria, entry screening process, and
the study intervention has been published recently.13
Objectives and outcomes
Our primary objective was to test the effect of Crataegus Special
Extract WS 1442 on submaximal exercise capacity at 6 months as
determined by the 6 min walk test. The 6 min walk test is a validated
measure of submaximal exercise capacity in which a study participant is
asked to walk at their best pace for 6 min along a designated 20 m
straight path. During the test, pre-specified verbal encouragements
(e.g. ‘you are doing very well’) were given at 30 s and 2 min intervals
to increase the likelihood that participants would achieve and maintain
their best walking pace.
The secondary objectives included: (i) physician and patient global
assessment of the change in heart failure symptoms from baseline on
a 7-point Likert scale (markedly, moderately, or mildly better; same;
mildly, moderately, or markedly better); (ii) disease-specific QOL as
determined by the Minnesota Living with Heart Failure Questionnaire
(MLHFQ); (iii) functional capacity as accessed by peak exercise oxygen
consumption (peak VO2) and anaerobic threshold during maximal car-
diopulmonary treadmill exercise testing using a modified Naughton
ramp protocol; (iv) functional capacity as subjectively assessed by
NYHA functional classification; (v) LVEF; (vi) mortality risk as deter-
mined by the Heart Failure Survival Score (HFSS);14 (vii) neurohor-
mone profile (plasma norepinephrine and brain natriuretic peptide);
(viii) oxidative stress (plasma F2a 8-isoprostane); (ix) inflammation
(plasma high-sensitivity C-reactive protein); (x) global QOL [as deter-
mined by the EuroQol-5D questionnaire (EQ5D)15]; (xi) utility for
health status [as determined by the utility component of the EQ5D
(Visual Analogue Scale)15], and (xii) hospitalizations (heart
failure-related and total) during the 6 month study period.
Randomization, blinding, and allocation
Eligible participants were randomized equally to either placebo or
hawthorn groups. The randomization code was computer-generated
in blocks of size 6 by the study biostatistician. The randomization list
was then given to the research pharmacist who was not associated
with the study. The research pharmacist dispensed the study medi-
cation, which was in blister packs provided by the manufacturer, and
enclosed it in numbered boxes as per the randomization scheme. All
study participants as well as all study personnel who assessed out-
comes worked with study data or administered tests or questionnaires
were unaware of the randomization list or treatment assignment.
Statistical methods and sample size
Baseline characteristics are reported, stratified by treatment group,
using means and SDs for continuous variables, and counts and percen-
tages for categorical variables. Balance between treatment groups on
baseline characteristics was tested using independent samples t-tests
for continuous variables and Fisher exact tests for categorical variables.
For continuous variables, the assumption of normality was checked
using the Shapiro–Wilks test. To investigate a change from baseline
in 6 min walk distance or secondary continuous outcomes, the differ-
ence between the 6 months and baseline measure was calculated. Ana-
lyses on these differences were performed using independent samples
t-tests between treatment groups.
Despite the entry criteria of an LVEF 40% on a clinically indicated
study obtained within the prior 12 months (see above), the baseline
study radionuclide ventriculogram performed after randomization
revealed an LVEF of greater than 40% in 38 study participants. Since
the baseline assessment of LVEF occurred after randomization, we
were not able to exclude these patients. Consequently, the effects
of study drug vs. placebo on 6 min walk distance and secondary out-
comes at 6 months were also evaluated by ANCOVA, adjusting for
baseline value and baseline LVEF. For physician and patient global
assessments and NYHA, the change over time was tested using the
Wilcoxon rank-sum test. For categorical secondary variables, Fisher
exact tests were first performed, followed by adjusted analyses using
Cochran–Mantel–Haenzel tests stratifying by LVEF (40 and
.40%). For ranked data (i.e. NYHA class), a Cochran–Armitage x2
for linear trend was performed. Analyses were conducted according
to the intention-to-treat principle when possible (i.e. for deaths, hos-
pitalizations and adverse events), however no imputation was per-
formed for missing values at 6 months. Data were entered into SPSS
Windows version 11 (SPSS, Chicago, IL, USA) and analysed using
SAS version 9 (Cary, NC: SAS Institute Inc.). For all analyses, two-sided
tests and a significance level of 0.05 were used. The experiment-wise
Type I error rate was protected only for the principal outcome
measure. No adjustments were made for multiple hypotheses testing
as the secondary outcomes were viewed as hypothesis generating.
Since the effect of hawthorn on 6 min walk distance had not been
studied previously, no such information was available to guide
sample size considerations. We selected 40 m (10% improvement)
as a clinically meaningful improvement in 6 min walk distance, based
on our anticipation of a mean baseline walk distance of 350–400 m
and no change in the control arm. The study was therefore designed
to have 80% power to detect a treatment difference of 39 m (85%
power to detect a treatment difference of 41 m) in 6 min walk dis-
tance, based on published standard deviations of 64 to 74 in similar
populations walking between 150 and 450 m,16 assuming a two-sided
alpha level of 0.05 and n ¼ 60 patients per treatment group. We cal-
culated retrospective power by substituting the observed pooled stan-
dard deviation of the change in 6 min walk distance from baseline to
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6 months to the hypothesized 40 m improvement, 120 patient total
sample size, and two-sided alpha level of 0.05. A similar retrospective
power analysis was done for the 82 patient subsample with baseline
LVEF 40%.
Results
Screening, enrolment, and withdrawals
We screened 5412 patients, of whom 120 met all eligibility criteria
and were randomized, 60 to the placebo and 60 to the hawthorn
group. Figure 1 document sources of recruitment for potential par-
ticipants, reasons for exclusions, and reasons for discontinuing the
intervention. The low proportion of recruited patients reflects the
broad screening of unselected patients presenting to our cardiol-
ogy clinics. Fifty-seven participants in the placebo group and 54
participants in the hawthorn arm completed all study visits. Adher-
ence to study medications was high with 98% of all participants
taking greater than 95% of all study medication and with no signifi-
cant differences between groups.
Sociodemographic and clinical
characteristics
In Table 1, we present the sociodemographic and clinical character-
istics of participants by treatment group. There were no significant
differences between treatment groups for any demographic or
clinical characteristics.
Figure 1 Patient Flow in the Randomized Controlled Trial.
S.M. Zick et al.992
Effects on blood pressure and heart rate
There were no significant between group differences for changes in
blood pressure [DSBPhawthorn –2.1+ 13.3 (mean+ standard devi-
ation), DSBPplacebo 0.8+13.2, P ¼ 0.26; DDBPhawthorn 20.8+
10.7, DDBP 0.9+ 11.4, P ¼ 0.45], or heart rate (DHRhawthorn
1.9+ 11.0, DHRplacebo 0.7+8.4, P ¼ 0.51) at rest over the 6
month study period.
Clinical and quality of life outcomes
Tables 2–4 present the results for the primary and secondary study
endpoints. In Table 2, we present all continuous outcomes (mean
difference at 6 months and adjusted mean 6 month difference by
LVEF and baseline variable of interest), in Table 3, physician and
patient global assessments and in Table 4, data on NYHA
classifications.
We found no significant difference between the placebo and
hawthorn groups in our primary outcome, change in 6 min walk
distance over the 6 month study period (P ¼ 0.61). This reflected
an absence of any statistically significant within group effect of haw-
thorn (14+62 m, 95% CI 3–31 m) or placebo (5+ 32 m, 95% CI
3–14 m) on 6 min walk distance. Using the observed pooled stan-
dard deviation of 49 m for the change in 6 min walk distance, this
study had greater than 99% power to have detected the hypoth-
esized 40 m difference in 6 min walk distance between treatment
groups. Moreover, using the observed pooled standard deviation
of 51.04 m for the change in 6 min walk distance for the 82 patients
with LVEF 40%, results in 93% power to detect the same 40 m
difference.
Other evaluations of functional capacity were similarly unim-
pressive, with no significant between group differences for
changes in peak exercise oxygen consumption (P ¼ 0.22) or
anaerobic threshold (P ¼ 0.67) by maximal cardiopulmonary
testing and no significant linear trend in the change in NYHA
(P ¼ 0.64).
There were no significant differences between any measure of
QOL or health utility—neither global nor disease-specific
(MLHFQ, patient or physician global assessment, EQ5D)—nor in
measures of neurohormonal activation (NE, BNP), oxidative
stress (8-isoprostane) or inflammation (hs-C-reactive protein).
We did find a difference (P ¼ 0.04, no adjustment for multiple
testing) in favour of hawthorn for LVEF in the analysis adjusting
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Table 1 Baseline characteristics
Characteristics Placebo (n 5 60), n (%) or mean+SD Hawthorn (n 5 60), n (%) or mean+SD P-value*
Sex 0.83
Men 44 (73) 46 (77)
Women 16 (27) 14 (23)
Age 57.8 (+9.0) 54.4 (+12.6) 0.10
Race 0.37
White 50 (83) 45 (75)
Blood pressure, mm Hg
Systolic 113 (+19) 109 (+15) 0.25
Diastolic 66 (+10) 66+10 0.76
Heart rate, bpm 71+11 68+11 0.14
NYHA class 0.72
II 33 (55) 30 (50)
III 27 (45) 30 (50)
LVEF, % 34.8 (+14.5) 36.2 (+15.1) 0.59
LVEF 40% 44 (73) 38 (63) 0.33
Six-minute walk test, m 374.0 (+52.4) 358.2 (+59.2) 0.13
Peak oxygen consumption, mL\kg\min 14.6 (+3.8) 14.7 (+3.5) 0.79
Medications
ACE inhibitor 46 (77) 48 (80) 0.82
ARB 11 (18) 9 (15) 0.81
ACE inhibitor or ARB 57 (95) 57 (95) 1.00
Beta-blocker 52 (87) 54 (90) 0.78
Digoxin 49 (82) 47 (78) 0.82
Loop diuretic 57 (95) 55 (92) 0.72
Spironolactone 39 (65) 39 (65) 1.00
Thiazide diuretic 10 (17) 11 (18) 1.00
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; ACE, angiotensin-converting enzyme; ARB, angiotensin-II receptor blockers.
*P-value based on independent sample t-test for continuous variables and Fisher exact tests for categorical variables.
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Table 2 HERB CHF results
Outcome Baseline Six month visit P-valuea P-valueb
Placebo (N 5 60),
Mean+ SD
Hawthorn (N 5 60),
Mean+ SD
Placebo (N 5 57),
Mean+ SD
Hawthorn (N 5 54),
Mean+ SD
Six minute walk test, m 374+52 358+59 379+52 371+89 0.35 0.61
MLHFQ
Total 47+21 49+20 40+20 43+23 0.62 0.46
Emotional 8.9+6.5 9.7+5.4 7.4+5.3 8.2+5.3 0.83 0.61
Physical 22.3+9.3 23.6+9.7 18.9+8.4 20.3+11.3 0.53 0.45
EQ-5D
Questionnaire score 8.90+2.1 9.4+1.9 8.6+1.9 9.3+2.0 0.51 0.18
Visual analogue scale 68+18.8 60+18.5 73+13.8 70+20.4 0.07 0.58




14.6+3.8 14.7+3.5 14.7+4.4 15.7+3.5 0.22 0.22
Anaerobic threshold,
mL/kg/min
10.0+3.2 10.4+2.6 10.1+2.8 10.1+2.5 0.49 0.67
HFSS 8.77+1.1 8.90+1.2 8.62+1.1 9.02+1.3 0.13 0.22
BNP, pg/mL 260+446 232+347 281+495 243+519 0.47 0.25
NE, pg/mL 445+231 388+194 512+447 444+312 0.38 0.50
hs-C-reactive protein,
pg/mL
8.9+6.6 9.3+6.5 8.5+6.1 9.2+6.9 0.86 0.77
8-isoprostanes, pg/mL 174+87 173+85 183+89 170+93 0.14 0.12
MLHFQ, Minnesota Living with Heart Failure Questionnaire; EQ-5D, (EuroQol) European quality of life instrument; LVEF, left ventricular ejection fraction; HFSS, Heart Failure
Survival Score; BNP, B-type natriuretic peptide; NE, norepinephrine.
aIndependent sample t-test of mean difference.
bANCOVA adjusted for baseline value of the variable of interest and for baseline LVEF (as a continuous measure) except forHFSS andLVEF which are onlyadjusted forbaseline variable.
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Table 3 HERB CHF global assessment results
Outcome Six month visit P-value(1)* P-value(2)*
Placebo, n (%)a Hawthorn, n (%)a
Patient global assessment 0.55 0.58
Markedly better 9 (16) 10 (19)
Moderately better 14 (25) 10 (19)
Mildly better 11 (20) 8 (15)
No change 17 (30) 18 (34)
Mildly worse 4 (7) 4 (8)
Moderately worse 1 (2) 3 (6)
Markedly worse 0 (0) 0 (0)
Physician global assessment 0.76 0.59
Markedly better 4 (7) 7 (13)
Moderately better 14 (25) 7 (13)
Mildly better 10 (18) 14 (26)
No change 22 (39) 14 (26)
Mildly worse 4 (7) 6 (11)
Moderately worse 1 (2) 2 (4)
Markedly worse 1 (2) 4 (7)
aPercentages may not add up to 100 due to rounding of digits.
*P-value based on Wilcoxon rank-sum test comparing placebo to hawthorn at 3 months (1) or 6 months (2) after study entry. Ratings were converted to ordinal values from 1
(markedly worse) to 7 (markedly better) for calculation.
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for baseline LVEF. This resulted from a slight drop in LVEF in the
placebo group with no change in the hawthorn group. Stratification
by LVEF (40 vs. 40%) revealed a decrease in LVEF in both LVEF
strata of the placebo group with a 3 to 4 EF unit relatively more
favourable change in each LVEF strata of the hawthorn group.
Moreover, when the primary and secondary outcomes were
restricted to the 82 patients with LVEF 40% the differences
between the hawthorn and placebo groups remained statistically
insignificant (Table 5).
Adverse events and hospitalizations
Adverse events and hospitalizations are displayed in Table 6. There
were no significant differences in total deaths, deaths due to CHF,
or deaths due to cardiovascular disease (CVD) between treatment
groups. We divided adverse events into cardiac categories (e.g.
angina and atrial fibrillation) and those that most commonly
occurred in the trial (e.g. infections). While there were significantly
more total adverse events in the hawthorn group (36 vs. 23,
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Table 4 HERB CHF NYHA results
Outcome Baseline visit Six month visit P-value* P-value**
Placebo, n (%)a Hawthorn, n (%)a Placebo, n (%)a Hawthorn, n (%)a
NYHA Class 0.56 0.64
I 0 (0) 0 (0) 4 (7) 8 (15)
II 33 (55) 30 (50) 31 (54) 23 (43)
III 27 (45) 30 (50) 22 (29) 21 (39)
IV 0 (0) 0 (0) 0 (0) 2 (4)
NYHA, New York Heart Association classification.
aPercentages may not add up to 100 due to rounding of digits.
*P-value based on Wilcoxon rank-sum test on the change in NYHA from baseline to 6 months after study entry.
**P-value based on Cochran–Armitage x2 for linear trend on the change in NYHA from baseline to 6 months after study entry.
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Table 5 HERB CHF results for patients with left ventricular ejection fraction 40%
Outcome Baseline Six month visit P-valuea P-valueb
Placebo (N 5 44),
mean+ SD
Hawthorn (N 5 38),
mean+ SD
Placebo (N 5 41),
mean+ SD
Hawthorn (N 5 33),
mean+ SD
Six minute walk test, m 373+51 347+54 377+51 352+88 0.88 0.96
MLHFQ
Total 43+20 52+19 38+18 47+23 0.53 0.20
Emotional 7.8+6.1 9.5+5.5 6.3+4.6 8.7+5.4 0.44 0.10
Physical 21.7+8.7 24.7+9.0 18.8+8.2 22.6+10.7 0.43 0.21
EQ-5D
Questionnaire score 8.6+1.9 9.3+2.0 8.3+2.0 9.3+1.8 0.70 0.15
Visual analogue scale 68+19.1 60+18.6 73+14.7 66+22.0 0.18 0.72




13.7+3.1 13.8+3.1 14.0+4.2 15.0+3.6 0.18 0.18
Anaerobic threshold,
mL/kg/min
9.4+3.2 9.9+2.6 9.8+2.2 9.8+2.7 0.88 0.83
HFSS 8.3+0.9 8.2+0.7 8.2+0.9 2.3+1.0 0.24 0.25
BNP, pg/mL 305+490 340+395 346+561 345+630 0.72 0.63
NE, pg/mL 455+240 427+197 500+399 517+352 0.83 0.81
hs-C-reactive protein, pg/mL 9.1+6.8 9.9+6.3 8.8+6.4 9.5+6.5 0.60 0.75
8-isoprostanes, pg/mL 179+84 169+88 174+79 167+102 0.60 0.59
aIndependent sample t-test of mean difference.
bANCOVA adjusted for baseline value of the variable of interest.
MLHFQ, Minnesota Living with Heart Failure Questionnaire; EQ-5D, (EuroQol) European quality of life instrument; LVEF, left ventricular ejection fraction; HFSS, Heart Failure
Survival Score; BNP, B-type natriuretic peptide; NE, norepinephrine.
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P ¼ 0.02), there was no significant difference in total cardiac events
or in any category of cardiac events, nor was there another specific
category of adverse events that differed in frequency between
placebo and hawthorn groups. There were 37 participants who
were hospitalized during the study period (range of one to four hos-
pitalizations) for non-elective reasons. We found no significant
difference in total hospitalizations between groups with 23 partici-
pants hospitalized in the hawthorn group and 14 participants hospi-
talized in the placebo group (P ¼ 0.11). Of the 37 participants, 22
were hospitalized for a reason directly related to their CHF. We
observed no significant difference in hospitalizations due to CHF
(P ¼ 0.24), for which 14 participants in the hawthorn groups were
hospitalized vs. 8 in the placebo group. We also found no significant
difference between either total (P ¼ 0.07) or CHF-related (P ¼
0.11) hospitalizations after adjusting for baseline LVEF.
Discussion
We found no benefit of a hawthorn extract, in the dose and for-
mulation used, on our primary endpoint, the 6 min walk test dis-
tance, when added to contemporary standard therapy in patients
with systolic chronic heart failure. Likewise, hawthorn extract
caused no difference in any index of QOL including heart failure
related or global QOL, patient and physician assessments, or
health utility measures. These results are consistent whether
evaluated in unadjusted analyses or in analyses that adjusted for
patients’ baseline LVEF and baseline value for each measure. We
also found no differences between hawthorn and placebo for
any secondary outcome except for LVEF, for which we observed
a modest difference in its change over the 6 month study period
in favour of hawthorn. As we did not adjust for multiple hypothesis
testing in secondary analyses, this should not be interpreted as sub-
stantial evidence for a positive effect of hawthorn on left ventricu-
lar function but rather as worthy of further study. Overall, the
difference in LV function resulted from a decrease in LVEF in the
placebo group and maintenance of LVEF in the hawthorn group.
The drop in LVEF in the placebo group was driven by a substantial
reduction in those patients whose initial LVEF was greater than
40%. Since all study subjects had clinical measurements of LVEF
of 40% or less prior to study entry, some of the reduction of
LVEF in these patients may have reflected a regression to the
mean.
In general, hawthorn appeared to be well tolerated. There were
no differences between placebo and hawthorn for cardiac-related
adverse events or in common AE categories including infections,
rashes, gastrointestinal complaints, or headaches. However, we
observed significantly more total adverse events in the hawthorn
group. The increased number of adverse events in the hawthorn
group was driven by miscellaneous events. The wide variety of
events in the hawthorn group appears unlikely to be explainable
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Table 6 Death, hospitalization, and other adverse events in HERB CHF
Adverse event Placebo (n 5 60), n (%) Hawthorn (n 5 60), n (%) P-Value(1)a P-Value(2)a
All deaths (within 6 months) 2 (3) 5 (8) 0.26 0.22
Deaths due to CHFb 1 (2) 1 (2) 1.0 0.92
Deaths due to CVDb 2 (3) 2 (3) 1.0 0.99
All hospitalizations (within 6 months) 14 (23) 23 (38) 0.11 0.07
Hospitalizations due to CHFb 8 (13) 14 (23) 0.24 0.11
All patients with any adverse events 23 (38) 36 (60) 0.02 0.02
All cardiac-related adverse events 12 (20) 12 (20) 1.0 0.98
Worsening CHF 5 (8) 5 (8) 1.0 0.81
Angina/chest pain 3 (5) 2 (3) 1.0 0.93
Syncopal event 2 (3) 3 (5) 0.65 0.61
Atrial fibrillation 2 (3) 2 (3) 1.0 0.98
Infectionsc 9 (15) 7 (12) 0.59 0.68
Headache 1 (2) 1 (2) 1.0 0.95
Rash 1 (2) 2 (3) 0.57 0.57
GI symptomsd 2 (3) 5 (8) 0.47 0.59
Musculoskeletale 1 (2) 2 (3) 0.59 0.48
Other adverse eventf 10 (17) 18 (30) 0.13 0.08
aP-values based on (1) Fisher exact tests comparing adverse or (2) Cochran–Mantel–Haenzel tests, stratified by LVEF (40 and .40%) events in hawthorn vs. placebo.
bOne death in the placebo group is due to both CHF and CVD; causes of death in the hawthorn group other than CVD or CHF are aplastic anaemia, renal failure, and unknown
causes.
cInfections include styes, URI, pneumonia, conjunctivitis, cellulitis, infected pilonidal cyst, dental abscess, and urosepsis.
dGI symptoms include: constipation, diarrhea, loose stool, nausea and vomiting.
eMusculoskeletal includes: sprain/strain of back, degenerative joint disease in knee.
fOther includes: pancreatitis, lightheadedness and hypotension, complication of diabetes, onset of diabetes, renal insufficiency with multiple cysts found on kidney, discharge of
defibrillator, elevated transaminases, narcotic dependency, thymus gland with diffuse nodular lymphoid hyperplasia, femoral artery stent for PVOD, superficial thrombophlebitis,
hyperthyroidism, dysphasia, prerenal azotemia, thrombocytopenia, replacement of defibrillator; small lesions (on pancreas, liver and kidneys), increased serum levels of AST and
total bilirubin, gout, leg ulcer from PVOD, plantar keratosis, venous thrombosis of the right great saphenous vein, phlebitis, lower extremity deep venous thrombosis. CVD,
cardiovascular disease.
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by a pharmacologic effect of hawthorn and may have occurred by
chance alone. In addition, there were no significant differences
between hawthorn and placebo in the number of deaths (all or
CHF related) nor in study participants hospitalized overall or for
CHF. Given the modest sample size of the present study, the possi-
bility of a type II error must be considered. In this regard, the stat-
istically insignificant increase in hospitalizations (total and CHF) in
the analysis stratified by baseline LVEF should be explored in future
studies.
Our results are in contrast to numerous earlier RCTs examining
the safety and efficacy of hawthorn extracts in systolic chronic
heart failure. A meta-analysis12 examining these RCTs concluded
that, ‘there is a significant benefit from hawthorn extract as an
adjunctive treatment for chronic heart failure.’ Overall, hawthorn
extracts were found to significantly decrease pressure–heart
rate product and maximal workload and to improve heart failure
related symptoms.12 There are numerous possible explanations
for the different findings in our trial. Previous RCTs with hawthorn
have failed to mandate contemporary, evidence-based, concomi-
tant medical therapy for heart failure in their control and active
treatment arms. In several studies, it is unclear or unspecified
which medications were allowed.17,18 Other studies have not
allowed any concomitant medications,19 or allowed only diuretics
as concomitant heart failure therapy,18,20,21 while remaining studies
have allowed, but not required (absent contraindications or intol-
erances), an ACE inhibitor.22– 24 No studies have required use of a
beta-blocker (absent contraindications or intolerances). When
concomitant therapies were allowed, no period of dose stabiliz-
ation was required. Hawthorn’s mechanism of action may have
considerable pharmacological overlap with several medications
regularly prescribed for heart failure such as beta-blockers or
ACE inhibitors. One trial has been conducted in which a hawthorn
extract (LI 132 at a dose of 300 mg three times daily) was directly
compared with the ACE inhibitor captopril (12.5 mg three times
daily) in 132 patients. Both groups experienced improved exercise
tolerance and a decrease in frequency of heart failure-related
symptoms. There were no significant differences in the
responses.25 Thus, hawthorn could have had clinical effects in
studies in which these concomitant medications were not used
that were masked by the effects of such medications in our study.
Earlier studies enrolled samples that were potentially less ill than
our study sample. Most prior trials did not specify how long a study
participant had to have heart failure before study entry. These
studies may have enrolled patients with recent acute heart
failure who were destined for recovery over the next few
months regardless of medical interventions. All but one prior
study24 enrolled only NYHA class II patients, excluding patients
with more advanced heart failure. By enrolling patients who
walked between 150 and 450 m on a screening 6 min walk test,
and by excluding patients with comorbidities (e.g. arthritis, periph-
eral vascular disease, etc.) that could limit exercise performance,
we identified a group of stable CHF patients that were neither
too ill nor too well to achieve measurable improvements in exer-
cise capacity with a successful intervention.
Differences between our results and previous hawthorn RCTs
could also be due to different exercise and QOL measures. The
principal exercise outcome in earlier studies was the change in
pressure-rate product (PRP) at constant, low-level bicycle exer-
cise.17,22 The smaller increase in PRP for the same level of external
work for hawthorn vs. placebo patients found in other RCTs rep-
resents greater exercise efficiency. However, this outcome
measure, the change in PRP, has minimal clinical relevance and
no known prognostic significance in patients with CHF.26 On the
other hand, the 6 min walk test distance is a surrogate measure
that provides relevant information about death27 and QOL,28 argu-
ably the two most clinically relevant outcome measures in heart
failure. Further, peak VO2 is an objective, reproducible measure
of maximal functional capacity, and is a strong, consistent, and
well-validated predictor of mortality in heart failure.29 No other
trial examining hawthorn for heart failure had a submaximal exer-
cise outcome or assessed peak VO2.
Many hawthorn trials have used patient and physician assess-
ments, but few have used either global or disease-specific QOL
measures that have been validated within the CHF population.
Without these measures, it is difficult to assess the impact of haw-
thorn on QOL (disease-specific and global), and impossible to
compare the QOL impact of hawthorn to other heart failure
therapies. In contrast, the HERB-CHF study utilized both global
(EQ5D) and disease-specific (MLHFQ) QOL scales. Both are well-
validated measures, and the MLHFQ has been used in numerous
clinical heart failure drug trials to evaluate clinical response.
It is possible that the negative results we observed in this study
are due to incorrect preparation or too low a dose of hawthorn
extract. Most studies examining Crataegus Special Extract WS
1442 have used similar or lower doses. However, one study24
examined the difference between a 900 and 1800 mg daily dose
of Crataegus Special Extract WS 1442 in patients with NYHA
class III CHF on maximal work load (bicycle exercise test), both
patients and physicians QOL assessments and safety. Both doses
were found to be statistically superior to placebo. The 1800 mg
dose was found to be superior to the 900 mg dose for both
patient and physician assessment of efficacy and tolerability.
However, there was no difference between doses for maximal
workload tolerated or a score of typical heart failure symptoms.
These results would appear to indicate that little is gained by sub-
stantially increasing the dose. Also, as with any herbal product
hawthorn extracts can be made in numerous fashions leading to
different constituent blends with potentially different medicinal
effects. We chose to use the Crataegus Special Extract WS 1442
preparation because it was widely utilized in Europe, had been
used the most in previous studies in chronic heart failure,12 and
was manufactured with high levels of quality control. As such, by
utilizing the Crataegus Special Extract WS 1442 preparation we
were able to compare our results to the majority of other
studies, have clinical relevance to patients and clinicians, and
offer considerable prior information on safety and tolerability.
However, other hawthorn preparations could produce other out-
comes and adverse effects than those presented in this study.
Limitations
Our study has several limitations. We did not assess baseline study
LVEF until after randomization and instead relied on LVEF
measures obtained for clinical indications within 12 months of
enrolment to determine LVEF for study entry. Consequently,
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some participants may have improved in the interim with corre-
sponding increases in their LVEF, although all continued to have
substantial clinical heart failure. The subsequent decline in LVEF
in those with baseline LVEF .40% suggests that some of the base-
line measurements overestimated LV function. We were limited
also by inadequate power to detect small effect sizes for secondary
outcomes. However, effect sizes observed for these outcomes
were all so small that clinically significant differences appear
unlikely.
Our study is much too small to provide a reliable estimate of the
effect of this hawthorn extract on mortality. The lack of an effect
on the 6 min walk test, peak VO2, and the Heart Failure Survival
Score, each a well-validated prognostic marker in chronic heart
failure, suggests that a mortality benefit would not be expected.
Our results appear to complement the results of SPICE, a random-
ized clinical trial comparing the same hawthorn extract used in
HERB CHF to placebo in 2681 patients with NYHA class II-III sys-
tolic heart failure and LVEF 35%, as reported in the European
Journal of Heart Failure. No effect of hawthorn was observed on
the principal outcome of time until first cardiac event, defined as
a composite of cardiac death, non-fatal myocardial infarction, and
hospitalization due to progressive heart failure.30
There is weak evidence from this study that hawthorn may have
a favourable effect on LVEF. A preparation that increases LVEF may
appear attractive to heart failure patients and their physicians.
However, without a proven mortality benefit, a heart failure medi-
cation should provide clear evidence of an improvement in symp-
toms, QOL, or functional capacity. As hawthorn—or more
specifically, this hawthorn extract at the dose studied—provided
none of these benefits, its use outside the context of a clinical
trial cannot be recommended.
Conclusion
In summary, the data from this study indicate that a hawthorn
extract, Crataegus Special Extract WS 1442, provides no clinical
benefit, at the dosing regimen evaluated, when given in addition
to standard evidence-based contemporary medical therapy to
patients with ambulatory symptomatic chronic heart failure. Haw-
thorn extract may be associated with an increase in non-cardiac
adverse events.
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